Monday, August 31, 2020

IPCA LABORATORIES - Q1 FY 21 RESULTS - REVIEW

 

IPCA LABORATORIES

Q1 FY 21 RESULTS REVIEW

 

About Ipca Laboratories:

Ipca is a fully integrated pharmaceutical company with a strong thrust on exports.

Ipca is vertically integrated and produces Finished Dosage Forms(FDFs) and Active Pharmaceutical Ingredients(APls).

Management                   

Premchand Godha              Chairman & M.D & CEO            

Ajit Kumar Jain           Joint Managing Director & CFO        

Key Financials of Ql FY21

   Standalone Net Total Income up 45% at Rs.1496.93crores.

   Consolidated Net Total Income up 41% at Rs.1546.49 crores.

   Indian formulations income up 8% at Rs.489.41 crores.

   Exports Income up 62% at Rs.773.89 crores.

   Standalone EBIDTA margin (before forex(gain)/Ioss) @39.65% in Q1 FY21 as against @19.91% in Q1 FY20.

   Consolidated EBIDTA margin @ 38.44% in Q1 FY21 as against @ 19.11% in Q1 FY20.

   Standalone Net Profit up 244% at Rs.453.64 cr.

  Consolidated Net Profit up 244% at Rs.445.68 cr

Q1 FY21 Revenue break-up (Rs. Cr)

Particulars     Q1 FY21        Q1 FY20        Growth

Formulations

Domestic       489.41          452.81          8%

Exports

Branded        133.52          91.63            46%

Institutional         88.67     27.32            225%

Generics              241.45   125.87          92%

Total Formulations 953.05 697.63   37%

APls

Domestic             203.04          65.70     209%

Exports                310.25          232.63   33%

Total      APls       513.29          298.33   72%

Subsidiaries         49.02            67.18     -27%

Other Operating Income 19.04 15.05      27%

Other Income             12.09     20.34     -41%

Consolidated Net Total Income 1546.49 1098.53 41%

 

Ipca Laboratories (in Rs. Cr.)

Jun '20

Mar '20

Jun '19

YOY

QOQ

Net Sales

1,534

1,074

1,078

42

43

P B T

546.64

114.58

168.37

225

377

Tax

99.89

29.2

37.35

167

242

Net Profit

446.75

85.38

131.02

241

423

Minority Interest

0.45

2.96

0.2

125

-84.8

Share Of P/L Of Associates

-1.07

-2.33

-1.59

-32.7

-54.08

FINAL NPT

446.13

86.01

129.63

244

419


25.27

25.27

25.27

0

0

Basic EPS

35.27

6.57

10.24

244

437

MP

2005





PE

14.22





VOLUMES

209000





52 Wk L/H

844.2

2175




 

Annual

Mar-20

Mar-19

Mar-18

Mar-17

Mar-16

Sales

4,649

3,773

3,258

3,156

2,867

Net Profit

611.37

444.03

243.65

202.8

96.2

 

Historical Prices




3M BEF

Current Price

%Gain / Loss

Open Price

1596

2032.25

27.33


1YR BEF



Open Price

969

2032.25

109.73


2YR BEF



Open Price

725.8

2032.25

180


3YR BEF



Open Price

414

2032.25

390.88

 

Share Holding Pattern in (%)







Standalone

Jun-20

Mar-20

Sep-19

Jun-19

Promoters

46.07

46.07

46.07

46.07

Pledged

0

0

0

0

FII/FPI

12.39

12.64

16.14

15.58

Total DII

31

30.62

26.89

27.64

Fin.Insts

0.03

0.04

0.04

0.03

Insurance Co

4.23

2.22

0.78

0

MF

22.82

23.14

21.52

22.25

Others DIIs

3.92

5.22

4.55

5.36

Others

10.54

10.66

10.9

10.7

Total

100

99.99

100

99.99

 

 

No comments:

Post a Comment